NJ drugmaker faces civil, criminal fines over drug

March 5, 2013 by Linda A. Johnson

(AP)—A New Jersey-based generic drug maker has agreed to pay $45 million to resolve criminal and civil liability charges for improperly marketing its weight-gain drug to frail seniors.

Officials from Woodcliff Lake-based Par Pharmaceutical Cos. pleaded guilty to a charge of criminal misbranding Tuesday in federal court in Newark.

Par officials admitted they improperly marketed their Megace ES drug for treating anorexia and malnutrition in geriatric patients who did not have AIDS. It's approved for helping .

The company has also agreed to enter into a five-year corporate integrity agreement with and to drop a lawsuit it filed against the U.S. government.

Par agreed in July to be acquired by an affiliate of the private investment firm TPG for $1.84 billion.

Explore further: Merck will pay $950M to settle Vioxx investigation

shares

Related Stories

Report: J&J will pay $2.2B in Risperdal settlement

July 20, 2012

(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Recommended for you

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.